3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
2
Recurrence
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Hematologic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Endometrioid
1
Breast Neoplasms
1
Advanced Solid Malignancy,
1
Interventions
Sunitinib
64
Nivolumab
42
pembrolizumab
36
Bevacizumab
32
Everolimus
31
Sorafenib
25
pazopanib
23
Axitinib
23
cabozantinib
14
aldesleukin
13
Ipilimumab
13
temsirolimus
11
Interferon alpha-2
11
Cyclophosphamide
10
avelumab
9
Magnetic Resonance Spectroscopy
9
Interleukin-2
9
lenvatinib
8
atezolizumab
8
Radiosurgery
8
Gemcitabine
8
Immunoglobulin G
7
Erlotinib Hydrochloride
7
Disulfides
6
fludarabine phosphate
5
Radiotherapy
5
Fluorodeoxyglucose F18
5
peginterferon alfa-2b
4
Vorinostat
4
Tyrosine Kinase Inhibitors
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Renal Cell
×
capivasertib
×
Clear all
No trials found.